JP2002527052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002527052A5 JP2002527052A5 JP2000575546A JP2000575546A JP2002527052A5 JP 2002527052 A5 JP2002527052 A5 JP 2002527052A5 JP 2000575546 A JP2000575546 A JP 2000575546A JP 2000575546 A JP2000575546 A JP 2000575546A JP 2002527052 A5 JP2002527052 A5 JP 2002527052A5
- Authority
- JP
- Japan
- Prior art keywords
- leptin
- amino acid
- amino acids
- bioconjugate
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 14
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 13
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 9
- -1 polyethylene Polymers 0.000 description 9
- 229920000573 polyethylene Polymers 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 229940039781 leptin Drugs 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 125000003827 glycol group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/172,644 | 1998-10-14 | ||
| US09/172,644 US6420339B1 (en) | 1998-10-14 | 1998-10-14 | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| PCT/US1999/024401 WO2000021574A2 (en) | 1998-10-14 | 1999-10-13 | Site-directed dual pegylation of proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002527052A JP2002527052A (ja) | 2002-08-27 |
| JP2002527052A5 true JP2002527052A5 (https=) | 2006-11-30 |
| JP4854851B2 JP4854851B2 (ja) | 2012-01-18 |
Family
ID=22628578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000575546A Expired - Lifetime JP4854851B2 (ja) | 1998-10-14 | 1999-10-13 | 改善された生物活性と生体適合性のためのタンパク質の部位特異的二重ポリエチレングリコール化 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6420339B1 (https=) |
| EP (1) | EP1121155B1 (https=) |
| JP (1) | JP4854851B2 (https=) |
| AT (1) | ATE463260T1 (https=) |
| AU (1) | AU757860B2 (https=) |
| CA (1) | CA2345027C (https=) |
| DE (1) | DE69942231D1 (https=) |
| WO (1) | WO2000021574A2 (https=) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841617B2 (en) | 2000-09-28 | 2005-01-11 | Battelle Memorial Institute | Thermogelling biodegradable aqueous polymer solution |
| US7087244B2 (en) | 2000-09-28 | 2006-08-08 | Battelle Memorial Institute | Thermogelling oligopeptide polymers |
| AU781460B2 (en) * | 1999-02-12 | 2005-05-26 | Amgen, Inc. | Glycosylated leptin compositions and related methods |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| KR100401296B1 (ko) * | 2000-12-27 | 2003-10-11 | 드림바이오젠 주식회사 | 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법 |
| EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| EP1425304B9 (en) * | 2001-07-11 | 2010-09-08 | Maxygen, Inc. | G-csf conjugates |
| WO2003093433A2 (en) * | 2002-05-02 | 2003-11-13 | Regents Of The University Of Minnesota | Fibrin-based biomatrix |
| AU2003233119A1 (en) * | 2002-05-08 | 2003-11-11 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| NZ542873A (en) * | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US7610156B2 (en) * | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7587286B2 (en) * | 2003-03-31 | 2009-09-08 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| AU2004271804B2 (en) * | 2003-09-12 | 2011-01-06 | Newron Sweden Ab | Treatment of disorders of the nervous system |
| EP1675871A2 (en) | 2003-10-10 | 2006-07-05 | Xencor Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
| BRPI0507169A (pt) * | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| AU2005229001A1 (en) * | 2004-03-23 | 2005-10-13 | Amgen Inc. | Chemically modified protein compositions and methods |
| US7632924B2 (en) * | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| WO2006091231A2 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| EP1836298B1 (en) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
| EP1836316A4 (en) | 2004-12-22 | 2009-07-22 | Ambrx Inc | PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE |
| BRPI0519430A2 (pt) | 2004-12-22 | 2009-02-10 | Ambrx Inc | hormânio do crescimento humano modificado |
| CN103520735B (zh) | 2004-12-22 | 2015-11-25 | Ambrx公司 | 包含非天然编码的氨基酸的人生长激素配方 |
| WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| KR20080027291A (ko) * | 2005-06-01 | 2008-03-26 | 맥시겐 홀딩스 엘티디 | 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법 |
| AU2006255122B2 (en) | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2005335491B2 (en) | 2005-08-18 | 2010-11-25 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
| DK2339014T3 (en) | 2005-11-16 | 2015-07-20 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
| EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| EP2064333B1 (en) | 2006-09-08 | 2014-02-26 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
| CN106008699A (zh) | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| JP5399906B2 (ja) | 2006-09-08 | 2014-01-29 | アンブルックス，インコーポレイテッド | 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| MX344166B (es) | 2008-02-08 | 2016-12-07 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| AR071169A1 (es) * | 2008-03-31 | 2010-06-02 | Council Scient Ind Res | Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas |
| KR20130116386A (ko) | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| WO2009149379A2 (en) * | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| BR122012024318A2 (pt) | 2008-09-26 | 2019-07-30 | Ambrx, Inc. | Polipeptídeos modificados de eritropoetina animal e seus usos |
| CN102272151B (zh) * | 2008-11-04 | 2014-08-20 | 詹森药业有限公司 | Crhr2肽激动剂及其用途 |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| WO2011005540A1 (en) | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
| HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| US20110105397A1 (en) * | 2009-11-04 | 2011-05-05 | Gengo Peter J | Method for treating heart failure with stresscopin-like peptides |
| BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
| MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
| WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| EA030886B1 (ru) | 2010-08-17 | 2018-10-31 | Амбркс, Инк. | Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| BR112013018628A2 (pt) * | 2011-01-26 | 2017-07-18 | Novo Nordisk As | derivados da leptina |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
| SI3045183T1 (sl) * | 2011-03-11 | 2018-11-30 | Genzyme Corporation | Pegiliran Apelin in njegove uporabe |
| US9140698B2 (en) | 2011-04-06 | 2015-09-22 | The Board Of Regents Of The University Of Texas System | Modulating bacterial MAM polypeptides in pathogenic disease |
| AU2012262488A1 (en) | 2011-05-31 | 2014-01-16 | Airware, Inc. | Re-calibration of AB NDIR gas sensors |
| CA2839512C (en) | 2011-06-17 | 2018-01-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| WO2013026015A1 (en) | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Muc1 ligand traps for use in treating cancers |
| US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| JP6162707B2 (ja) | 2011-10-24 | 2017-07-12 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法 |
| WO2013071049A1 (en) | 2011-11-10 | 2013-05-16 | Trustees Of Boston College | Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| CA2867593A1 (en) * | 2012-03-16 | 2013-09-19 | Belrose Pharma, Inc. | Polymeric conjugates of c-1 inhibitors |
| CN108686203A (zh) | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| EP2890402B1 (en) | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| RS58010B1 (sr) | 2012-09-27 | 2019-02-28 | Childrens Medical Ct Corp | Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US9789156B2 (en) | 2013-03-11 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics |
| TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| HUE063647T2 (hu) | 2016-09-12 | 2024-01-28 | Amryt Pharmaceuticals Inc | Eljárások anti-leptin semlegesítõ antitestek detektálására |
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| CA3177086A1 (en) | 2017-06-22 | 2018-12-27 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| CA3111576A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| JP2022512746A (ja) | 2018-10-19 | 2022-02-07 | アンブルックス，インコーポレイテッド | インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用 |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| CA3123872A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| CA3128081A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| AU2020338947A1 (en) | 2019-08-27 | 2022-03-31 | Tonix Pharma Limited | Modified TFF2 polypeptides |
| EP4117732A1 (en) | 2020-03-11 | 2023-01-18 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用 |
| CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
| US20250341516A1 (en) | 2024-05-01 | 2025-11-06 | BioLegend, Inc. | Compositions for use with multiple fluorophores and methods of using |
| WO2025250943A1 (en) * | 2024-05-30 | 2025-12-04 | Penguin Bio Corp. | Leptin variants and methods of use thereof |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| JP2657113B2 (ja) | 1989-10-16 | 1997-09-24 | アムジエン・インコーポレーテツド | 幹細胞因子 |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| EP0578774B1 (en) | 1991-04-05 | 1998-07-29 | The Board Of Regents Of The University Of Washington | Monoclonal antibodies to stem cell factor receptors |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| CA2211656A1 (en) | 1995-01-31 | 1996-08-08 | Margret B. Basinski | Anti-obesity proteins |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| FI973162L (fi) | 1995-01-31 | 1997-09-30 | Lilly Co Eli | Liikalihavuutta vastustavia proteiineja |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766596A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| AU5539596A (en) | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| ES2093593T1 (es) * | 1995-05-05 | 1997-01-01 | Hoffmann La Roche | Proteinas obesas (ob) recombinantes. |
| AU5737696A (en) | 1995-05-08 | 1996-11-29 | Chiron Corporation | Nucleic acids for treating obesity |
| CA2221824A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
| CA2224867A1 (en) | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| ATE259650T1 (de) | 1995-08-17 | 2004-03-15 | Amgen Inc | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| PT866720E (pt) | 1995-11-22 | 2004-06-30 | Amgen Inc | Proteina ob para aumentar a massa do tecido mole |
| AU1406497A (en) | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| IL124831A0 (en) * | 1995-12-27 | 1999-01-26 | Genentech Inc | Ob protein derivatives having prolonged half-life |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| KR20000016402A (ko) | 1996-06-06 | 2000-03-25 | 피터 기딩스 | 렙틴(ob단백질)의 프레그먼트 |
| CA2263826A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| WO1998016545A1 (en) | 1996-10-11 | 1998-04-23 | Eli Lilly And Company | Therapeutic proteins |
| WO1998024896A2 (en) | 1996-12-06 | 1998-06-11 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| JP4199421B2 (ja) | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
-
1998
- 1998-10-14 US US09/172,644 patent/US6420339B1/en not_active Expired - Lifetime
-
1999
- 1999-10-13 AU AU14475/00A patent/AU757860B2/en not_active Expired
- 1999-10-13 DE DE69942231T patent/DE69942231D1/de not_active Expired - Lifetime
- 1999-10-13 AT AT99970331T patent/ATE463260T1/de not_active IP Right Cessation
- 1999-10-13 WO PCT/US1999/024401 patent/WO2000021574A2/en not_active Ceased
- 1999-10-13 CA CA2345027A patent/CA2345027C/en not_active Expired - Lifetime
- 1999-10-13 EP EP99970331A patent/EP1121155B1/en not_active Expired - Lifetime
- 1999-10-13 JP JP2000575546A patent/JP4854851B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527052A5 (https=) | ||
| CA2345027A1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
| JP2001514858A5 (https=) | ||
| AU683121B2 (en) | Compounds with growth hormone releasing properties | |
| WO2002047715A3 (en) | Compositions of peptide crystals | |
| Sundelin et al. | Amino acid sequence homologies between rabbit, rat, and human serum retinol-binding proteins. | |
| JP2002513556A5 (https=) | ||
| EP2145897A3 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
| JP2003510366A5 (https=) | ||
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| JP2003527311A5 (https=) | ||
| EP1693382A3 (en) | Melanocortin 1 receptor selective compounds | |
| AU9174398A (en) | Peptides | |
| CA2365533A1 (en) | Diagnosis and treatment of neuroectodermal tumors | |
| WO1997009343A3 (fr) | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers | |
| JP2006506097A5 (https=) | ||
| JP2006506942A5 (https=) | ||
| JP2002516284A5 (https=) | ||
| JP2002522512A5 (https=) | ||
| ATE536878T1 (de) | Herstellung einer therapeutischen zusammensetzung | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| JP2002513802A5 (https=) |